$22.31
▲ +1.6% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?
Adaptive Biotechnologies Insider Sold Shares Worth $2,389,164, According to a Recent SEC Filing
Overview
52-week range
$9.78
$21
100% of range
Avg surprise (last 3)
+25.5%
Avg reaction (last 2)
-2.5%
0% positive
Latest IV / EM
73%
EM ±16.7% · $23 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.13 | $-0.16 | +18.8% | +35.0% | -5.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.06 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.17 | $-0.24 | +29.2% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.20 | $-0.28 | +28.6% | — | 0.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.31 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.33 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.35 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.33 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Jul 29, 2026 | Jun/2026 | AMC | -$0.13 | -$0.17 | +23.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | — | $94M | $59M | $52M | — | $46M | $43M |
| Cost of revenue | $19M | — | $18M | $18M | $17M | — | $17M | $19M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-19M | — | $10M | $-25M | $-30M | — | $-33M | $-47M |
| Net income | $-20M | — | $10M | $-26M | $-30M | — | $-32M | $-46M |
| EPS (diluted) | $-0.13 | — | $0.06 | $-0.17 | $-0.20 | — | $-0.22 | $-0.31 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $78M | $70M | $55M | $43M | $51M | $48M | $38M | $60M |
| Inventory | $11M | $10M | $10M | $8M | $9M | $8M | $12M | $13M |
| Total current assets | $292M | $300M | $281M | $262M | $256M | $284M | $308M | $352M |
| Total assets | $506M | $513M | $491M | $497M | $511M | $539M | $559M | $585M |
| Long-term debt | $125M | $127M | $129M | $130M | $132M | $132M | $133M | $132M |
| Total liabilities | $282M | $288M | $286M | $317M | $321M | $337M | $335M | $343M |
| Total equity | $216M | $219M | $204M | $180M | $190M | $203M | $224M | $242M |